The FDA, despite a positive recommendation from its independent advisory panel, on May 8th indefinitely delayed approval of biologic drug Provenge, an experimental drug that works by mobilizing the body’s natural immune system to fight prostate cancer.
The FDA asked for additional clinical data on Provenge before approving it, Dendreon said in a press release. While […]
-
Tags
- Cancer News
- Cancer Story
- breast-cancer
- breast_cancer
- american_cancer_society
- cervical_cancer
- cancer_patients
- journal_cancer
- prostate_cancer
- metastatic_breast_cancer
- cancer_treatment
- colorectal_cancer
- john_edwards
- cervical_cancer_vaccine
- cancer_drugs
- breast_cancer_patients
- colon_cancer
- cancer_vaccine
- word_cancer
- cancer_vaccines
- cancer_therapies
- cancer_researchers
- cancer_deaths
- elizabeth_edwards
- cancer
- breast_cancer_cases
- cancer-drug
- breast_cancer_research
- BREAST-CANCER-RISK
- cancer_center
-
Archives